Last updated: October 31, 2026
Avage is a prescription topical formulation of tazarotene 0.1% cream, a topical retinoid used primarily for facial fine wrinkling, mottled hyperpigmentation, and benign facial lentigines. Its commercial trajectory has been shaped by generic substitution, limited brand differentiation, and the absence of publicly reported standalone revenue. The product has no meaningful biologic or biosimilar exposure. Its principal commercial risk is generic erosion across the topical retinoid market.
What is Avage and what does it treat?
Avage contains tazarotene, a retinoid prodrug converted in the skin to tazarotenic acid. The product was approved in the United States as a 0.1% cream for the topical treatment of facial fine wrinkling, facial mottled hyper- and hypopigmentation, and benign facial lentigines in patients using a comprehensive skin-care and sun-avoidance program.[1]
Avage is distinct from other tazarotene products:
| Product |
Active ingredient |
Dosage form |
Primary U.S. indication |
| Avage |
Tazarotene 0.1% |
Cream |
Facial fine wrinkling and pigmentation disorders |
| Tazorac |
Tazarotene 0.05% or 0.1% |
Gel or cream |
Acne vulgaris and plaque psoriasis, depending on formulation |
| Fabior |
Tazarotene 0.1% |
Foam |
Plaque psoriasis |
| Generic tazarotene |
Tazarotene |
Cream, gel, foam |
Depends on the approved abbreviated application |
The product’s cosmetic dermatology positioning distinguishes it from tazarotene products used for acne and psoriasis. That distinction supports some prescribing segmentation, but it has not created a durable commercial barrier against generic tazarotene cream.
What is the FDA regulatory status of Avage?
Avage was approved through a new drug application for topical use. The FDA-approved label identifies tazarotene cream 0.1% as the active product and includes warnings concerning pregnancy, photosensitivity, irritation, and use on eczematous skin.[1]
Key regulatory characteristics include:
| Regulatory attribute |
Avage position |
| FDA pathway |
New drug application |
| Active ingredient |
Tazarotene |
| Strength |
0.1% |
| Dosage form |
Topical cream |
| Prescription status |
Prescription drug |
| Biologic classification |
Not applicable |
| Biosimilar pathway |
Not applicable |
| Main regulatory substitutes |
Generic tazarotene cream and other topical retinoids |
| Regulatory differentiation |
Cosmetic dermatology labeling and cream vehicle |
Tazarotene is not a biologic. Biosimilar competition is therefore irrelevant. Competitive pressure comes from abbreviated new drug applications, therapeutic substitution, pharmacy benefit management, and other topical retinoids such as tretinoin and adapalene.
What is the Orange Book status of Avage?
The FDA Orange Book is the primary source for determining whether Avage has listed patents, exclusivity, and therapeutically equivalent generic products.[2] The product’s commercial life is consistent with a mature prescription product whose original regulatory and patent protections have elapsed or lost practical market value.
The relevant Orange Book questions are:
- Whether the Avage reference product remains listed as an active reference standard.
- Whether patents are listed against the relevant NDA.
- Whether FDA-rated therapeutically equivalent generic products are available.
- Whether the brand remains commercially marketed by the NDA holder.
An Orange Book listing does not by itself establish commercial availability. Products may remain listed after marketing has ceased, and a listed reference drug can retain regulatory relevance even when its brand revenue is minimal.
What patents protect Avage?
The original tazarotene patent estate was based on retinoid chemistry and product development conducted before Avage’s approval. Those core patents are no longer a meaningful barrier to generic entry in the United States.
Core compound and formulation protection
Public patent records associate tazarotene with early retinoid patents covering compounds, pharmaceutical compositions, and dermatological uses. The key economic point is that these patents were filed decades before the current market and have passed their ordinary term, subject to any applicable patent-term adjustment or regulatory extension.
| Protection category |
Commercial status |
| Tazarotene compound patents |
Historical protection; no longer a practical U.S. entry barrier |
| Cream formulation patents |
Historical or expired protection |
| Acne and psoriasis method-of-use patents |
Relevant to other tazarotene products, not generally sufficient to protect Avage’s cosmetic indication |
| Manufacturing know-how |
Potential process advantage, but not a broad market exclusivity right |
| Trade dress and brand |
Limited protection against generic substitution |
Avage’s remaining commercial value does not depend on a strong exclusionary patent estate. It depends on brand recognition, physician familiarity, payer treatment, distribution, and any continued availability of the branded product.
When did Avage lose exclusivity?
Avage’s exclusivity loss occurred over a longer period than a single event because regulatory exclusivity, patent protection, and generic commercialization operate on different timelines.
The main phases were:
| Period |
Market event |
Commercial effect |
| Initial approval period |
Avage entered the prescription dermatology market |
Brand controlled the labeled product |
| Patent-protection period |
Tazarotene and related formulations received patent protection |
Generic entry remained constrained |
| Post-patent period |
Patent barriers weakened or expired |
ANDA applicants could pursue approval |
| Generic commercialization period |
Generic tazarotene products reached the market |
Brand price and volume pressure increased |
| Mature generic period |
Multiple topical retinoid alternatives became available |
Avage became a niche or low-revenue product |
The precise commercial loss-of-exclusivity date depends on the specific NDA, patent listing, pediatric extension, settlement terms, and first commercial generic launch. FDA regulatory exclusivity and patent expiry should not be treated as the same date.
How many patents cover Avage?
No current patent count should be used as a proxy for Avage’s commercial protection without confirming the applicable Orange Book edition and NDA record. Historical tazarotene patents existed, but the material question for investors and competitors is whether any unexpired, enforceable patent remains listed against the Avage reference product.
The product has no apparent modern patent moat comparable to newer dermatology products protected by proprietary delivery systems, device components, or novel combinations. Its topical cream vehicle is technically reproducible, and tazarotene is a well-characterized small molecule.
What formulations are protected by Avage?
Avage uses a cream vehicle containing tazarotene 0.1%. Formulation-related differentiation is commercially narrower than compound protection.
Potential formulation variables include:
- Tazarotene concentration.
- Cream excipients.
- Skin penetration characteristics.
- Irritation profile.
- Stability and packaging.
- Manufacturing controls.
- Container-closure compatibility.
These features can support formulation patents or regulatory differentiation when they produce a measurable clinical or pharmaceutical advantage. They do not automatically prevent approval of a generic product with a different inactive-ingredient profile.
Generic tazarotene applicants generally seek pharmaceutical equivalence and bioequivalence or the applicable FDA standard for topical products. A generic does not need to copy every inactive ingredient to compete with the reference product.
What generic entry risks exist for Avage?
Avage faces high generic-entry risk because:
- Tazarotene is a small molecule.
- The product is a conventional topical cream.
- The original patents are old.
- Dermatology prescribing is highly substitution-sensitive.
- Payers can prefer lower-cost topical alternatives.
- Patients and prescribers can switch to tretinoin, adapalene, or other tazarotene formulations.
- Manufacturing does not require sterile fill-finish or complex biologic production.
The commercial impact of generic entry is usually more severe for a low-volume branded topical than for a differentiated specialty product. A brand can retain some demand through physician preference or a favorable vehicle, but this rarely supports premium pricing when pharmacies can substitute a therapeutically equivalent generic.
Have companies challenged Avage through Paragraph IV filings?
A Paragraph IV certification is the mechanism by which an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. The existence of a Paragraph IV filing does not guarantee litigation, and a litigation settlement does not necessarily produce a commercial launch.
The available public regulatory framework does not support treating Avage as an active, high-value Paragraph IV litigation asset. Any historical ANDA disputes would need to be evaluated by NDA, patent number, filer, filing date, and settlement terms. The commercial conclusion remains the same: Avage does not present the profile of a currently protected, high-growth branded product.
What patent litigation affects Avage?
Avage has limited visible litigation significance compared with newer dermatology products. The main litigation risks historically associated with topical retinoids have involved:
- Patent validity and infringement.
- Formulation similarity.
- Labeling and method-of-use claims.
- Generic substitution.
- Patent-term calculations.
- Product liability and dermatological adverse-event allegations.
There is no basis to assign material current litigation value to Avage without a live case, an active listed patent, or a disclosed settlement that restricts generic launch.
What is the financial trajectory of Avage?
AbbVie does not report Avage revenue as a standalone product in its public financial statements. The product is not separately identified in the company’s principal revenue disclosures, which means revenue, gross margin, prescription volume, and cash-flow contribution cannot be calculated from public filings.[3]
The financial trajectory is therefore best characterized qualitatively:
| Financial phase |
Expected commercial pattern |
| Pre-generic brand period |
Higher price and stronger gross margin |
| Early generic entry |
Rapid decline in branded prescriptions and net price |
| Mature generic period |
Low or immaterial branded revenue |
| Post-commercialization or discontinuation |
Regulatory listing may persist without meaningful sales |
Avage is unlikely to be material to AbbVie’s consolidated revenue. AbbVie’s financial results are driven by products such as Skyrizi, Rinvoq, Botox, Vraylar, and other large commercial franchises, not legacy topical retinoids.[3]
The economic value of Avage may persist through:
- Residual brand prescriptions.
- Contract manufacturing or distribution arrangements.
- Portfolio rationalization value.
- Licensing or divestiture opportunities.
- Use as a reference product for regulatory purposes.
None of these factors supports a conclusion that Avage is a meaningful current revenue driver without product-level sales data.
How does Avage compare with competing topical retinoids?
| Product |
Commercial strength |
Main advantage |
Main weakness |
| Avage |
Mature and limited |
Recognized tazarotene cream brand |
Generic competition and narrow revenue base |
| Generic tazarotene |
Cost-driven |
Lower price |
Variable availability and limited brand support |
| Tretinoin |
Broad and established |
Large prescribing base across acne and photoaging |
Irritation and multiple competing formulations |
| Adapalene |
Strong acne position |
Favorable tolerability and broad consumer awareness |
Less direct positioning for facial photodamage |
| Tazorac |
Dermatology-focused |
Tazarotene brand recognition |
Generic and formulation competition |
| Fabior |
Niche |
Foam delivery for psoriasis |
Narrow indication and generic pressure |
Avage’s principal competitive disadvantage is not clinical obsolescence. It is weak commercial differentiation in a market where prescribers have several topical retinoid options and payers can favor lower-cost products.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest. Tazarotene cream requires controlled formulation, uniform drug distribution, stability, packaging, and topical performance. Those requirements create execution risk but not a durable barrier comparable to sterile injectables, complex biologics, or proprietary drug-device systems.
Potential remaining barriers include:
- Demonstrating topical bioequivalence or equivalent performance.
- Controlling particle size and drug dispersion.
- Managing irritation and stability.
- Meeting FDA chemistry, manufacturing, and controls requirements.
- Securing reliable dermatology distribution.
- Establishing preferred payer placement.
These are development and commercialization hurdles, not strong exclusion rights.
What generic launch scenarios are most likely?
The most likely scenario is continued erosion of branded Avage demand, with generic tazarotene and therapeutic substitutes capturing most price-sensitive prescriptions.
Three scenarios are commercially relevant:
- Generic-dominant market: Generic tazarotene becomes the default pharmacy option and Avage retains limited physician-directed use.
- Brand niche survival: Avage remains available for patients or prescribers who prefer its vehicle, labeling, or established brand.
- Commercial withdrawal: The brand is discontinued or becomes difficult to source while the active ingredient remains available through generics.
The third scenario is plausible for a mature topical brand when manufacturing, distribution, and promotional costs exceed residual net sales.
Key Takeaways
- Avage is tazarotene 0.1% cream for facial fine wrinkling and pigmentation disorders.
- Its market is mature and exposed to generic substitution.
- The original tazarotene patent estate does not appear to provide a current U.S. commercial moat.
- Biosimilar risk is not relevant because Avage is a small-molecule topical drug.
- FDA Orange Book status should be checked at the NDA and patent-listing level before making a precise exclusivity determination.
- Avage revenue is not separately disclosed in AbbVie’s public filings.
- The product is unlikely to be material to AbbVie’s consolidated financial results.
- Generic tazarotene, tretinoin, adapalene, Tazorac, and Fabior are the principal competitive references.
- Manufacturing complexity is moderate but does not create a durable barrier to entry.
- The likely financial path is low residual brand revenue, declining market share, and continued substitution by lower-cost topical products.
FAQs About Avage Market Exclusivity and Commercial Value
Is Avage still protected by patents?
Avage’s original compound and formulation protections are historical. A current patent conclusion requires review of the applicable FDA Orange Book record and any later-issued patent covering the specific product.
Is Avage interchangeable with generic tazarotene?
Generic tazarotene may be therapeutically equivalent when FDA-rated as substitutable for the relevant reference product. Formulation, inactive ingredients, labeling, and product availability can differ.
Does Avage have biosimilar competition?
No. Avage contains a chemically synthesized small molecule, not a biologic. Competition occurs through generic drug applications and therapeutic substitution.
Who owns the Avage brand?
Avage was associated with Allergan and later became part of AbbVie’s legacy pharmaceutical portfolio after AbbVie acquired Allergan. Product marketing status should be confirmed through current FDA and company records.
What is the investment value of Avage?
Avage is unlikely to have material standalone investment value without a current commercial agreement, active patent litigation, or separately disclosed revenue stream. Its value is primarily as a mature dermatology asset with limited residual brand demand.
References
- U.S. Food and Drug Administration. (n.d.). Avage (tazarotene) cream, 0.1% prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
